Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995535 · ClinicalTrials.gov registry record · Phase 2
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
A Phase 2 study of Opioid Use and Opiate Withdrawal Syndrome, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT05995535 is a Phase 2 study of Opioid Use and Opiate Withdrawal Syndrome that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 150 participants, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05995535, a Phase 2 study of Opioid Use and Opiate Withdrawal Syndrome, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
Conditions Studied
Interventions
- DRUG LFX/PGB
- DRUG LFX/PLA-PGB
Study Locations (2)
Maryland
- Mountain Manor Treatment Center - Baltimore
Pennsylvania
- University of Pennsylvania, Treatment Research Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05995535
The ClinicalTrials.gov registry entry for NCT05995535 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid Use appearing as the primary indexed condition, and to 2 interventions - of which LFX/PGB is the first listed.
NCT05995535 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05995535 about?
NCT05995535 is a clinical study titled "Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal". A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after compl...
What is the current status of trial NCT05995535?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-01-01. Estimated completion is 2026-08-31.
What conditions does trial NCT05995535 study?
This clinical trial studies the following conditions: Opioid Use, Opiate Withdrawal Syndrome.
What interventions are being tested in trial NCT05995535?
The interventions under investigation include: LFX/PGB (DRUG), LFX/PLA-PGB (DRUG).
Who is sponsoring clinical trial NCT05995535?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05995535 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
RECRUITING · Phase 2
-
Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
RECRUITING · Phase 2
-
Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure
ACTIVE NOT RECRUITING · Phase 2
-
Managing Opioid Related Sleep Apnea With Acetazolamide
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.